A total of 135 batches of potassium chloride extended-release capsules were recalled by Glenmark Pharmaceuticals and American Health Packaging due to the risk of cardiac arrest caused by the failed dissolution of the capsules6. Glenmark recalled 114 batches, while American Health Packaging recalled 21 batches on behalf of BluePoint Laboratories.
Potassium Chloride Extended-Release Capsules, manufactured by Glenmark Pharmaceuticals and distributed by American Health Packaging on behalf of BluePoint Laboratories, were recalled due to a risk of cardiac arrest. The recall was issued because the capsules might not dissolve properly, potentially leading to high potassium levels (hyperkalemia) and an irregular heartbeat.
High potassium levels, or hyperkalemia, can induce an irregular heartbeat, which in severe cases can lead to cardiac arrest, according to the FDA. This condition has led to the recall of 135 batches of potassium chloride extended-release capsules, as the failed dissolution of the capsules could potentially cause hyperkalemia.